Duloxetine use in painful conditions

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 8, 2011, Pages 1333-1340

  Marcus, Dawn A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

antidepressant; arthritis; back pain; clinically meaningful; osteoarthritis

Indexed keywords

CARBAMAZEPINE; CELECOXIB; DICLOFENAC; DULOXETINE; GABAPENTIN; IBUPROFEN; INDOMETACIN; LAMOTRIGINE; LIDOCAINE; MORPHINE; OXCARBAZEPINE; PARACETAMOL; PAROXETINE; PREGABALIN; TRAMADOL;

ANALGESIA; ARTHRITIS; ARTICLE; CHRONIC PAIN; CONSTIPATION; DIABETIC NEUROPATHY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FIBROMYALGIA; HEADACHE; HUMAN; HYPERHIDROSIS; INFLAMMATORY PAIN; INSOMNIA; KNEE OSTEOARTHRITIS; LOW BACK PAIN; MUSCULOSKELETAL PAIN; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PAIN; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; SOMNOLENCE; TREATMENT INDICATION; TREATMENT OUTCOME; TRIGEMINUS NEURALGIA; XEROSTOMIA;

ANALGESIA; ANALGESICS; ANIMALS; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HUMANS; LOW BACK PAIN; OSTEOARTHRITIS; PAIN; RETROSPECTIVE STUDIES; THIOPHENES; TREATMENT OUTCOME;

EID: 79955829989     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.580739     Document Type: Article

References (49)

1. Miller A, Rabe-Jablonska J.The effectiveness of antidepressants in the treatment of chronic non-cancer pain - a review.Psychiatr Pol 2005;39:21-32 (Pubitemid 40364900)
2. Atkinson JH, Patel SM, Meyer JM, et al.Is there a therapeutic window with some antidepressants for analgesic response? Curr Pain Headache Rep 2009;13:93-9
3. Jus A, Bujalska M, Makulska-Nowak HE.Modification of fentanyl analgesia by antidepressants.Pharmacology 2010;85:48-53
4. Tomic MA, Vuckovic SM, Stepanovic-Petrovic RM, et al.Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice.Eur J Pharmacol 2010;628:75-82
5. Goldstein FJ.Adjunct to opioid therapy.J Am Osteopath Assoc 2002;102(Suppl 3):S15-21
6. Barkin RL, Fawcett J.The management challenges of chronic pain: the role of antidepressants.Am J Ther 2000;7:31-47
7. Bajwa ZH, Simopoulos TT, Pal J, et al.Low and therapeutic doses of antidepressants are associated with similar response in the context of multimodal treatment of pain.Pain Physician 2009;12:893-900
8. Brannan SK, Mallinckrodt CH, Brown EB, et al.Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.J Psychiatr Res 2005;39:43-53 (Pubitemid 39422285)
9. Jones CK, Peters SC, Shannon HE.Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents.J Pharmacol Exp Ther 2005;312:726-32 (Pubitemid 40189572)
10. Jones CK, Peters SC, Shannon HE.Synergistic interactions between the dual serotonergic, noradrenergic reuptake inhibitor duloxetine and the non-steroidal anti-inflammatory drug ibuprofen in inflammatory pain in rodents.Eur J Pain 2007;11:208-15 (Pubitemid 44820900)
11. Pettersen VL, Zapata-Sudo G, Raimundo JM, et al.The synergistic interaction between morphine and maprotiline after intrathecal injection in rats.Anesth Analg 2009;109:1312-17
12. Ho KY, Tay W, Yeo MC, et al.Duloxetine reduces morphine requirements after knee replacement surgery.Br J Anaesth 2010;105:371-6
13. Namaka M, Leong C, Grossberndt A, et al.A treatment algorithm for neuropathic pain: an update.Consult Pharm 2009;24:885-902
14. Attal N, Cruccu G, Baron R, et al.EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.Eur J Neurol 2010;17:1113-23
15. Arnold LM, Lu Y, Crofford LJ, et al.A double-blind, multicenter trial comparing duloxetine with placebo in the treatmen tof fibromyalgia patients with or without major depressive disorder.Arthritis Rheum 2004;50:2974-84 (Pubitemid 39209537)
16. Arnold LM, Rosen A, Pritchett YL, et al.A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.Pain 2005;119:5-15 (Pubitemid 41752960)
17. Russell IJ, Mease PJ, Smith TR, et al.Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial.Pain 2008;136:432-44
18. Chappell AS, Bradley LA, Wiltse C, et al.A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia.Int J Gen Med 2009;1:91-102
19. Hauser W, Petzke F, Uceyler N, Sommer C.Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis.Rheumatology 2011;50:532-43
20. Marangell LB, Clauw DJ, Choy E, et al.Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine.Pain 2011;152:31-7
21. Raskin J, Pritcherr YL, Wang F, et al.A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.Pain Med 2005;6:346-56 (Pubitemid 41727332)
22. Goldstein DJ, Lu Y, Detke MJ, et al.Duloxetine vs.placebo in patients with painful diabetic neuropathy.Pain 2005;116:109-18 (Pubitemid 40828506)
23. Wernicke JF, Pritchett YL, DSouza DN, et al.A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.Neurology 2006;67:1411-20 (Pubitemid 44632065)
24. Gao Y, Ning G, Jia WP, et al.Duloextine versus placebo in the treatment of patients with diabetic neuropathic pain in China.Chin Med J 2010;123:3184-92
25. Kajdasz DK, Iyengar S, Desaiah D, et al.Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies.Clin Ther 2007;29(Suppl):2536-46 (Pubitemid 350299457)
26. Hall JA, Wang F, Oakes TM, et al.Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials.Expert Opin Drug Saf 2010;9:525-37
27. Vranken JH, Hollmann MW, van der Vegt MH, et al.Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial.Pain 2011;152:267-73
28. Mignogna MD, Adamo D, Schiavone V, et al.Burning mouth syndrome responsive to duloxetine: a case report.Pain Med 2011;12:466-9
29. Farrar JT, Young JP, LaMoreaux L, et al.Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.Pain 2001;94:149-58 (Pubitemid 33016608)
30. Farrar JT, Pritchett YL, Robinson M, et al.The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders.J Pain 2010;11:109-18
31. Salaffi F, Stancati A, Silvestri CA, et al.Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale.Eur J Pain 2004;8:283-91 (Pubitemid 38859657)
32. Hoffman DL, Sadosky A, Dukes EM, Alvir J.How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy? Pain 2010;149:194-201
33. Chandran P, Pai M, Blomme EA, et al.Pharmacological modulation of movement-evoked pain in a rat model of osteoarthritis.Eur J Pharmacol 2009;613:39-45
34. Sullivan MD, Bentley S, Fan MY, Gardner G.A single-blind, placebo run-in study of duloxetine for activity-limiting osteoarthritis pain.J Pain 2009;10:208-13
35. Chappell AS, Ossanna MJ, Liu-Seifert H, et al.Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial.Pain 2009;146:253-60
36. Chappell AS, Desaiah D, Liu-Seifert H, et al.A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee.Pain Pract 2011;11:33-41
37. Skljarevski V, Ossanna M, Liu-Seifert H, et al.A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain.Eur J Neurol 2009;16:1041-8
38. Skljarevski V, Zhang S, Desaiah D, et al.Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial.J Pain 2010;11:1282-90
39. Skljarevski V, Zhang S, Chappell AS, et al.Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study.Pain Med 2010;11:648-57
40. Skljarevski V, Desaiah D, Liu-Seifert H, et al.Efficacy and safety of duloxetine in patients with chronic low back pain.Spine 2010c;35:E578-85
41. Mazza M, Mazza O, Pazzaglia C, et al.Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain.Expert Opin Pharmacother 2010;11:1049-52
42. Brunton S, Wang F, Edwards SB, et al.Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies.Drug Saf 2010;33:393-407
43. Jensen MP, Smith DG, Ehde DM, Robinson LR.Pain site and the effects of amputation pain: further clarifying the meaning of mild, moderate, and severe pain.Pain 2001;91:317-22 (Pubitemid 32241153)
44. Zelman DC, Dukes E, Brandenburg N, et al.Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy.Pain 2005;115:29-36
45. Paul SM, Zelman DC, Smith M, Miaskowski C.Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints.Pain 2005;113:37-44 (Pubitemid 40038444)
46. Serlin RC, Mendoza TR, Nakamura Y, et al.When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function.Pain 1995;61:277-84
47. Li KK, Harris K, Hadi S, Chow E.What should be the optimal cut points for mild, moderate, and severe pain? J Palliat Med 2007;10:1338-46 (Pubitemid 350308638)
48. Given B, Given CW, Sikorskii A, et al.Establishing mild, moderate and severe scored for cancer-related symptoms: how consistent and clinically meaningful are interference-based severity cut-points? J Pain Symptom Manage 2008;35:126-35
49. Scascighini L, Toma V, Dober-Spielmann S, Sprott H.Multidisciplinary treatment for chronic pain: a systematic review of interventions and outcomes.Rheumatology 2008;47:670-8 (Pubitemid 351619211)